Pipeline

Imsidolimab (ANB019): Anti-IL-36R DEVELOPMENT STAGE & ANTICIPATED MILESTONES THERAPEUTIC INDICATION COMMERCIAL RIGHTS ANTIBODY PROGRAM DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Phase 1 Data Presented at EAACI 2018 GALLOP: Phase 2 Data To Be Presented At Medical Conference in 2021 Phase 3 Initiation Anticipated Mid-2021 POPLAR: Phase 2 Top-Line Data Announced March 2021No Further Clinical Development Currently Planned EMERGE: Interim Topline Phase 2 Data Anticipated End 2021 INSPIRE: Topline Phase 2 Data Anticipated 2022 ACORN: Phase 2 Initiated Q2 2021Topline Data Anticipated H1 2022 Generalized Pustular Psoriasis Palmoplantar Pustulosis Acne Vulgaris ANB030: Anti-PD-1 Agonist Phase 1 Top-LineData AnticipatedH2 2021 Phase 2 Initiation Anticipated in Q4 2021 Phase 2 Initiation Anticipated in Q4 2021 Vitiligo Alopecia Areata JEMPERLI (dostarlimab):Anti-PD-1 Antagonist US BLA and EU MAAApproved April 2021 BLA Accepted Q1 2021FDA Approval Anticipated H2 2021 FIRST: Ongoing OPAL: Ongoing dMMR Pan-Tumor Ovarian Cancer dMMR Endometrial Cancer PERLA: Ongoing NSCLC Cobolimab (GSK4069889): Anti-TIM-3 Antagonist COSTAR: Dostarlimab Combination Trial Ongoing GSK4074386: Anti-LAG-3 Antagonist CITRINO: Dostarlimab Combination Trial Ongoing Immuno-Oncology TSR-075: Anti-PD-1/ LAG-3 Bispecific IND-Enabling Studies Ongoing Immuno-Oncology CC-90006: Anti-PD-1 Agonist Ongoing Psoriasis Undisclosed Ongoing Inflammation ANB032: Anti-BTLA Modulator Inflammatory Diseases NSCLC HARP: Phase 2 Initiated Q2 2021Topline Data Anticipated H2 2022 Hidradenitis Suppurativa Ichthyosis EGFRi-Mediated Skin Toxicity Phase 1 Top-LineData AnticipatedH1 2022